InflaRx N.V.
izicopan
ANCA-associated vasculitis
Resolved
110days ago
Phase 2 readout · Mar 19, 2026
What's at stake
Phase 2 trial results for izicopan in ANCA-associated vasculitis are due Mar 19, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aR”